<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625958</url>
  </required_header>
  <id_info>
    <org_study_id>SAFARI 4</org_study_id>
    <nct_id>NCT05625958</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery</brief_title>
  <acronym>SAFARI4</acronym>
  <official_title>Multicentre, Non-randomised Clinical Study Evaluating the Efficacy and Safety of Cilioscleral Interposition Device v2.2 in Glaucoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciliatech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciliatech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of implanting a new&#xD;
      version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering&#xD;
      intraocular pressure (IOP) in patients with primary open and narrow angle glaucoma who have&#xD;
      failed at least one class of topical medical therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      35 patients will be included in this 36 months interventional study.&#xD;
&#xD;
      All patients shall be indicated for glaucoma surgery alone (not combined with cataract), and&#xD;
      will undergo incisional glaucoma therapy, including a simplified surgical technique allowing&#xD;
      the placement of an interposition supraciliary permanent device.&#xD;
&#xD;
      Several patient data like safety events, IOP, visual capacity or associated pharmacological&#xD;
      treatments will be recorded pre and post-operatively all along the follow-up.&#xD;
&#xD;
      Purpose is to ensure device safety, and verify IOP and associated pharmacological treatment&#xD;
      reduction after surgery, and evolution along follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess post-op IOP reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of eyes with &gt;= 20% decrease in mean-Diurnal-IOP from baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma, Narrow Angle</condition>
  <arm_group>
    <arm_group_label>Cilioscleral Interposition Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any patients corresponding to inclusion / exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cilioscleral Interposition Device</intervention_name>
    <description>Surgical placement of SV22 cilioscleral interposition device in the supraciliary space</description>
    <arm_group_label>Cilioscleral Interposition Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of POAG Schafer 1 to 4&#xD;
&#xD;
          -  Medicated IOP â‰¥ 21&#xD;
&#xD;
          -  naive of any prior glaucoma surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory, congenital, traumatic, neovascular, ICE syndrome, angle closure and&#xD;
             Schaffer 1 and 2 glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian GARCIA FEIJOO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica San Carlos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier BENOIT</last_name>
    <phone>+33635550153</phone>
    <email>o.benoit@cilia.tech</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>February 10, 2023</last_update_submitted>
  <last_update_submitted_qc>February 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

